EXELIXIS INC (EXEL) Stock News

USA - NASDAQ:EXEL - US30161Q1040 - Common Stock

34.54 USD

-4.71 (-12%)

Last: 10/20/2025, 6:44:09 PM

34.6 USD

+0.06 (+0.17%)

After Hours: 10/20/2025, 6:44:09 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

EXEL Latest News, Press Relases and Analysis

All

Press Releases

13 days ago - By: Chartmill

News Image

EXELIXIS INC (NASDAQ:EXEL) Identified as a Quality Value Stock by Fundamental Screening

17 days ago - By: Chartmill

News Image

EXELIXIS INC (NASDAQ:EXEL) Stands Out as an Affordable Growth Stock

9 hours ago - By: Benzinga

Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results

11 hours ago - By: Benzinga - Mentions: CCM CLLS GMAB ADXN ...

Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session

17 hours ago - By: Exelixis, Inc.

Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet

3 days ago - By: Exelixis, Inc.

Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025

6 days ago - By: The Motley Fool

The Ultimate Biotech Stock to Buy With $50 Right Now

21 days ago - By: The Motley Fool - Mentions: AXSM

Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years

a month ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

a month ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

a month ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

a month ago - By: Zacks Investment Research

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

a month ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

a month ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

2 months ago - By: The Schall Law Firm

EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with the Schall Law Firm

2 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

2 months ago - By: Exelixis, Inc.

Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development

2 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

2 months ago - By: Yahoo Finance

Exelixis, Inc. (EXEL) Halts Phase 3 STELLAR-305 Trial

2 months ago - By: Zacks Investment Research - Mentions: ALKS

Why Is Alkermes (ALKS) Up 4.7% Since Last Earnings Report?

2 months ago - By: Exelixis, Inc.

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September

2 months ago - By: Zacks Investment Research

Why Is Exelixis (EXEL) Up 3.8% Since Last Earnings Report?

2 months ago - By: Zacks Investment Research - Mentions: NVS MRK

Can Label Expansion of Cabometyx Fuel Further Growth for EXEL?

2 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

2 months ago - By: Zacks Investment Research - Mentions: MRK

Exelixis vs. Merck: Which Oncology Stock Is a Better Pick as of Now?